Celgene's triplet therapy of Pomalyst, or pomalidomide, Takeda's Velcade, or bortezomib, and dexamethasone, a treatment indicated for multiple myeloma patients who have undergone at least a single treatment containing Revlimid, or lenalidomide, has received the approval of Health Canada.
Canada approves Celgene's Pomalyst-based regimen for multiple myeloma
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.